ERBB2 and ovarian carcinoma: The expression of miR-125b is downregulated in various human cancers including glioblastoma, prostate cancer, ovarian cancer, and breast cancer by suppressing oncogenes such as EST1, ERBB2, ERBB3, and BAK1 as its targets [50, 51].